We are live on
!
Find out more
XT
XTX Topco Portfolio holdings
AUM
$5.75B
1-Year Est. Return
30.56%
This Fund
S&P 500
This Quarter
Est. Return
+0.17%
1 Year Est. Return
+30.56%
3 Year Est. Return
+70.38%
5 Year Est. Return
+43.83%
10 Year Est. Return
–
AUM
$3.81B
AUM Growth
+$1.88B
(+98%)
Cap. Flow
+$1.94B
Cap. Flow
% of AUM
50.99%
Top 10 Holdings %
Top 10 Hldgs %
5.52%
Holding
3,983
New
1,493
Increased
1,108
Reduced
652
Closed
727
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$25.6M |
| 2 |
JPMorgan Chase
JPM
|
+$21.7M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$19.7M |
| 4 |
Kroger
KR
|
+$17.9M |
| 5 |
T-Mobile US
TMUS
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$11.3M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$8.42M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$8.34M |
| 4 |
Cisco
CSCO
|
+$8.02M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$8.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.84% |
| 2 | Technology | 16.54% |
| 3 | Industrials | 11.45% |
| 4 | Healthcare | 11.32% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Smith Micro Software
SMSI
$14M
| $21K | ﹤0.01% |
7,789
-786
| -9% | -$2.58K |
|
|
JF
3052
J and Friends Holdings
JF
$15.8M
| $21K | ﹤0.01% |
+23,105
| New | +$22.2K |
|
|
LMFA
3053
DELISTED
LM Funding America
LMFA
| $21K | ﹤0.01% |
1,890
+1,111
| +143% | +$26.6K |
|
3054
Aprea Therapeutics
APRE
$7.6M
| $20.7K | ﹤0.01% |
+24,304
| New | +$29.8K |
|
3055
Barnwell Industries
BRN
$13.7M
| $20.6K | ﹤0.01% |
18,603
+2,290
| +14% | +$2.72K |
|
|
FBGL
3056
FBS Global
FBGL
$7.56M
| $20.5K | ﹤0.01% |
+21,506
| New | +$15K |
|
3057
BioCardia
BCDA
$11.6M
| $20.4K | ﹤0.01% |
16,290
+113
| +0.7% | +$153 |
|
3058
CollPlant Biotechnologies
CLGN
$6.2M
| $20.3K | ﹤0.01% |
+14,381
| New | +$29.4K |
|
|
DLXY
3059
Delixy Holdings
DLXY
$6.14M
| $19.9K | ﹤0.01% |
+22,504
| New | +$20.9K |
|
|
SBFM
3060
Sunshine Biopharma
SBFM
$3.04M
| $19.9K | ﹤0.01% |
+1,616
| New | +$25.5K |
|
|
UZX
3061
Linkage Global
UZX
$14.4M
| $19.7K | ﹤0.01% |
+10,714
| New | +$20.2K |
|
|
DXST
3062
Decent Holding Inc
DXST
$4.96M
| $19.6K | ﹤0.01% |
+565
| New | +$20K |
|
3063
BT Brands
BTBD
$7.42M
| $19.5K | ﹤0.01% |
+13,940
| New | +$22.9K |
|
|
OFAL
3064
OFA Group
OFAL
$2.87M
| $19.5K | ﹤0.01% |
+29,870
| New | +$26.2K |
|
|
SCNI
3065
Scinai Immunotherapeutics
SCNI
$1.36M
| $19.4K | ﹤0.01% |
+27,294
| New | +$31.1K |
|
3066
Silo Pharma
SILO
$5.03M
| $19.3K | ﹤0.01% |
+3,793
| New | +$28K |
|
3067
Planet Image International
YIBO
$68.1M
| $19.3K | ﹤0.01% |
20,279
+713
| +4% | +$836 |
|
3068
Fenbo Holdings
FEBO
$9.4M
| $19.3K | ﹤0.01% |
14,267
-1,168
| -8% | -$996 |
|
3069
Cytosorbents Corp
CTSO
$23.3M
| $19K | ﹤0.01% |
+29,682
| New | +$22.8K |
|
|
ADGM
3070
Adagio Medical Holdings
ADGM
$9.94M
| $18.8K | ﹤0.01% |
+18,103
| New | +$21.5K |
|
|
ETS
3071
Elite Express Holding Inc
ETS
$49.2M
| $18.8K | ﹤0.01% |
38,048
+18,821
| +98% | +$12.2K |
|
3072
Getty Images
GETY
$171M
| $18.6K | ﹤0.01% |
+13,889
| New | +$23.9K |
|
|
DEVS
3073
DELISTED
DevvStream Corp
DEVS
| $18.6K | ﹤0.01% |
+13,568
| New | +$25K |
|
3074
Tevogen Bio Holdings
TVGN
$23.6M
| $18.4K | ﹤0.01% |
+1,114
| New | +$29K |
|
|
HXHX
3075
Haoxin Holdings
HXHX
$5.79M
| $18.3K | ﹤0.01% |
+30,909
| New | +$25.5K |
|
Similar funds
HW
AAM
RWM
SAM
PP
VH
TSW
KIM
XTX Topco's Q4 2025 Portfolio in Review
As of Q4 2025, XTX Topco held 3,983 positions worth $3.81B, up 98% from $1.93B the previous quarter. Its ten largest holdings account for 5.5% of the portfolio.
XTX Topco deployed $1.94B of net new capital in Q4 2025, opening 1,493 new positions and adding to 1,108 existing holdings. Its largest new stake was T-Mobile US: 74,738 shares worth $15.2M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 14% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $8.34M trimmed.
- XTX Topco's largest Q4 2025 buy was T-Mobile US: 74,738 shares worth $15.2M.
- XTX Topco added most to Procter & Gamble in Q4 2025, an estimated $25.6M increase.
- XTX Topco's biggest Q4 2025 reduction was Bristol-Myers Squibb, cutting an estimated $8.34M.
- XTX Topco fully exited Johnson & Johnson in Q4 2025, selling an estimated $11.3M.
- XTX Topco's ten largest holdings make up 5.5% of its $3.81B portfolio in Q4 2025.
- XTX Topco opened 1,493 new positions and closed 727 in Q4 2025.
- XTX Topco's portfolio value rose 98% quarter-over-quarter to $3.81B.
Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.